Trial Profile
Pilot study of the significance of PTEN expression in patients with hormone refractory prostate cancer (HRPC) treated with Cetuximab as monotherapy for 8 weeks, followed by Docetaxel plus Cetuximab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2012
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 29 Mar 2012 Actual end date (31 Mar 2011) added as reported by European Clinical Trials Database.
- 29 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 27 Jul 2011 New trial record